Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Channing Judith Paller, M.D.
Assistant Professor of Oncology
Expertise: Bladder Cancer, Kidney Cancer, Medical Oncology, Testicular Cancer, Urological Oncology
Research Interests: TGF-beta receptor inhibitor and tumor microenvironment; natural products including mistletoe, pomegranate, vitamin C, vitamin D, and muscadine grape skin extract; aurora kinase inhibition; phase I combination drug trial design ...read more
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
The Bunting Blaustein Cancer Research Building
Appointment Phone: 410-614-3977
1650 Orleans Street
Baltimore, MD 21231 map
Johns Hopkins Outpatient Center
601 N. Caroline St.
Baltimore, MD 21287 map
Sibley Memorial Hospital
Appointment Phone: 202-660-6500
5255 Loughboro Road, NW
Washington, DC 20016 map
Dr. Channing J. Paller is a medical oncologist at Sibley Memorial Hospital and an assistant professor of oncology at the Johns Hopkins University School of Medicine. She is board certified in internal medicine and medical oncology and practices out of the Prostate Cancer Multidisciplinary Clinic at Sibley in Washington, D.C., the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD and the Bunting-Blaustein Cancer Research Building in Baltimore, MD.
Dr. Paller has an expertise in various kinds of cancer, including bladder, kidney, prostate and testicular, as well as other urological care.
Dr. Paller earned her medical degree from Harvard Medical School. She completed a residency in internal medicine at Johns Hopkins University School of Medicine, followed by a fellowship in hematology and oncology. In addition, Dr. Paller completed a rotation with the chief of the Investigational Drug Branch at the National Cancer Institute (NCI) Cancer Therapy Evaluation Program and a rotation with the associate director for regulatory science in the office of oncology drug products at the Food and Drug Administration. She also completed rotations at the Weizmann Institute of Israel’s department of biological regulation, the Massachusetts General Hospital endocrine unit and McCord Hospital in South Africa where she participated in the Harvard AIDS project.
Dr. Paller was selected for both a 2011-2012 Young Investigator Award by the American Society of Clinical Oncology and for the 2011-12 Eastern Cooperative Oncology Group Paul Carbone Award. Dr. Paller is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.
Dr. Paller’s research focuses on evaluating new therapies for prostate cancer, particularly combination therapies that engage the immune system. She is the principal investigator on two multi-site clinical trials and was the first author on the NCI Investigational Drug Steering Committee publication, “Consensus Recommendations on the Phase I Combination Clinical Trials of the Clinical Trial Design Task Force.” She was the chair for the oral abstract session on genitourinary cancer at the 2015 Annual Meeting of the American Society of Clinical Oncology and received the 2015 Passano Clinician Scientist Award for early stage research that is already making a contribution to science.
- Assistant Professor of Oncology
- Assistant Professor of Urology
Departments / Divisions
Centers & Institutes
- MD, Harvard Medical School (2005)
- Johns Hopkins University School of Medicine / Medicine (2008)
- Johns Hopkins University School of Medicine / Hematology and Oncology (2012)
- American Board of Internal Medicine / Internal Medicine (2008)
- American Board of Internal Medicine / Medical Oncology (2010)
Research & Publications
Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA. A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12. PMCID: PMC3549301.
Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):28-33. doi: 10.1038/pcan.2013.40. Epub 2013 Oct 8. PMCID: PMC3945997.
Paller, C., Bradbury, P.A., Ivy, P., Seymour, L., LoRusso, P., Baker, L., Rubinstein, L., Huang, E., Collyar, D., Groshen, S., Reeves, S., Ellis, L.M., Sargent, D., Rosner, G.L., LeBlanc, M., Ratain, M.J. The Design of Phase 1 Combination Trials: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. Clinical Cancer Research. 2014, 20(16): 4210–4217. PMCID: PMC4135521.
Paller CJ, Kanaan YM, Beyene DA, Naab TJ, Copeland RL, Tsai HL, Kanarek NF, Hudson TS. Risk of Prostate Cancer in African American Men: Evidence of Mixed Effects of Dietary Quercetin by Serum Vitamin D Status. Prostate. 2015 Sep;75(13):1376-83. PMCID: NIHMS689470.